Summary box
► In 2017, only 64% of the global estimated incident cases of tuberculosis (TB) were reported worldwide, the remaining 36% of 'missing' cases were either undiagnosed, untreated or unreported. ► Analysis of the patient cascade of care in India and South Africa suggests that these 'missed' patients are not really missing; most are actively engaging the health system (public and private) but not adequately managed. ► National TB control programmes need to identify gaps and weaknesses along the entire patient care cascade, addressing barriers to appropriate diagnosis, linkages to treatment postdiagnosis while strengthening both public and private healthcare sectors, and bridging the gap between provider knowledge and practice. ► Integration of TB services within universal health coverage is critical for identifying and managing missing patients with TB.
AbSTrACT Tuberculosis (TB) remains an enormous public health concern globally. India and South Africa rank among the top 10 high TB burden countries with the highest absolute burden of TB, and the second highest rate of TB incidence, respectively. Although the primary drivers of TB transmission vary considerably between these two countries, they do indeed share common themes. In 2017, only 64% of the global estimated incident cases of TB were reported, the remaining 36% of 'missing' cases were either undiagnosed, untreated or unreported. These 'missing TB cases' have generated much hype for the challenges they present in achieving the End TB Strategy. Although India and South Africa have indeed made significant strides in TB control, analysis of the patient cascade of care clearly suggests that these 'missed' patients are not really missing-most are actively engaging the health system-the system, however, is failing to appropriately manage them. In short, quality of TB care is suboptimal and must urgently be addressed, merely focusing on coverage of TB services is no longer sufficient. While the world awaits revolutionary vaccines, drugs and diagnostics, programmatic data indicate that much can be done to accelerate the decline of TB. In this perspective, we compare and contrast these two national epidemics, and explore barriers, with a particular focus on the role of health systems in finding the missing millions.
Tuberculosis (TB) remains an enormous public health concern causing disease in an estimated 10 million people globally in 2017. 1 In addition, TB is one of the top 10 causes of death worldwide, and has been the leading cause of death from a single infectious agent for the past 5 years, surpassing even that of HIV/AIDS. 2 Such statistics are disconcerting given the reality that TB is not a new disease but rather one that has plagued populations for millennia, and especially since the majority of people who develop TB can be cured with a timely diagnosis and appropriate management. 2 The WHO's End TB Strategy and the United Nations' Sustainable Development Goals share a common aim to end the global TB epidemic, targeting an 80% reduction in TB incidence by 2030 compared with 2015. 2 At the current global decline in TB incidence of just 2% per annum, these targets will almost certainly be unattainable. 1 India and South Africa rank among the top 10 high TB burden countries. With 2.7 million new cases in 2018, India has the highest absolute burden of TB.
1 With 567 new cases per 100 000 population, South Africa has the second highest rate of TB incidence. 1 Despite these top ranks, and collectively accounting for 31% of the world's burden of TB, and 37% of TB deaths, 1 the nature of the epidemic in South Africa and India is considerably different (table 1) . In this perspective, we compare and contrast these two national epidemics, and explore barriers, with a particular focus on the role of health systems in finding the missing millions.
IndIA
India's TB epidemic is driven by poor social conditions, notably poverty, overcrowding, malnutrition and tobacco smoking. 3 HIV is not a major driver of the Indian TB epidemic. Government investments in health are low, at approximately 1% of the national gross domestic product. 4 Despite the high TB burden, India is still reliant on old tools. For example, India only recently switched to daily drug regimens, having used intermittent regimens for decades. While rapid molecular testing is being scaled up, the country performs about 10 smears for every Xpert MTB/RIF test (which is a much superior rapid molecular test). 3 5 The Indian healthcare system is complex and highly heterogeneous, comprising formal and informal, private and public sector providers. 6 While free TB care is available in the public sector via a vertically run directly observed treatment, short course (DOTS) programme called Revised National TB Control Program (RNTCP), an estimated 50% of patients with TB are managed outside of RNTCP. 7 8 More recent data suggest that the proportion of patients with TB managed in the private sector might be even higher. TB drug sales in the private market suggest that over 2.2 million patients with TB may be managed in the private health sector each year, which is twice the number managed in the public sector. 9 Several systematic reviews highlight the magnitude and reasons for poor diagnostic and treatment outcomes in India. An average patient with TB experiences a median diagnostic delay of 55 days, after consulting almost three healthcare providers. 6 Another recent systematic review of 47 studies assessed quality of TB care. In 10 of 22 studies assessing providers' knowledge, less than half of the providers surveyed had correct knowledge on the use of sputum smears for TB diagnostic purposes. 10 In three of four studies evaluating self-reported practices, less than 25% of providers reported ordering a smear in patients with chest symptoms, and in 11 of 14 studies assessing treatment, less than one-third exhibited correct knowledge of the standard treatment for drug-susceptible TB. 10 A recent analysis of the cascade of TB care in India reported that in 2013 (figure 1), 72% of the estimated 2.7 million cases presented to government TB diagnostic services. Only 45% of estimated TB cases completed treatment. Of the 55% of cases for which treatment was not completed, half did not access diagnostic services. 11 The residual 28% that did not seek care in the public sector are thought to account for much of the missing TB cases in India. A considerable proportion of these cases are treated by private sector providers. India's private healthcare sector is fragmented, unregulated and comprises diverse types of providers, from allopathic (or Western medicine) doctors to practitioners of complementary medicine as well as informal healthcare providers with little or no formal qualifications; quality of TB care is subsequently often suboptimal. 3 12 In a systematic review conducted by Satyanarayana et al, 11 studies reported higher levels of TB knowledge and optimal provider practices among providers in the public sector, as compared with private sector. 10 Das et al further confirmed the substandard levels of care in the private sector. Using standardised (simulated) patients in large studies in multiple cities, they showed that only about a third of TB cases are correctly managed in the private sector. Their study revealed a substantial know-do gap between private providers' knowledge and practices related to TB diagnosis and treatment. 12 13 Recent standardised patient studies, covering four Indian cities, provide additional insights on how Indian private pharmacies manage patients with suspected or known TB. 14 15 Correct management of the simulated patients ranged from 13% to 62%, increasing with the certainty of the TB diagnosis. Antibiotics were frequently dispensed over the counter to simulated patients, with 16%-37% receiving such drugs across the cases. On a positive note, these studies showed that no pharmacy dispensed first-line anti-TB drugs. A common thread across all the simulated patient studies of TB in India is the low rates of TB testing by a variety of private providers, even when patients present with textbook description of suspected TB. Instead, empirical, broad-spectrum antibiotic and non-specific therapies was the norm. Thus, even when patients seek care, they get missed, or have a delayed diagnosis.
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SouTH AfrICA South Africa shares many of India's social problems and weaknesses in the healthcare system, but, unlike India, its TB epidemic is primarily driven by its convergent HIV epidemic. In 2016, South Africa's HIV prevalence was 12.7% with an estimated antiretroviral therapy (ART) coverage of 56%. 16 South Africa had the highest number of HIV-associated TB cases worldwide in 2017, with 59.9% of incident TB cases coinfected with HIV.
1 HIV-positive TB mortality accounted for 71.8% of deaths among patients with TB.
1 Traditional cohort analysis reports that 75% of patients started on treatment are successfully treated. However, Naidoo et al conducted a detailed cascade of care analysis on 2013 programmatic data and found that just 53% of the estimated TB cases resulted in successful treatment completion (figure 2). 17 18 Their study revealed the following stepwise losses along the pathway in the public sector, from care seeking to treatment completion: 5% were not able to access TB tests, 13% did not receive a TB diagnosis, 12% were not initiated on treatment and 17% failed to successfully complete treatment. 18 The small percentage of cases unable to access diagnostic services in South Africa is a reflection of the extensive network of free primary healthcare facilities (mostly run by nurses) in the country. 18 However, the losses reported along the patient cascade of care are a reflection of weak health systems. In fact, the findings of numerous studies have alluded to diagnostic delay or poor implementation of guidelines, reinforcing the importance of health systems strengthening within the realm of TB control. In 2015, five years after the incorporation of the recommendation that TB-HIV coinfected patients initiate ART irrespective of CD4 count, 15.5% of patients with TB-HIV did not initiate ART, 19 only 38%
BMJ Global Health of newly enrolled HIV-positive patients received isoniazid preventive therapy (IPT) in 2015. 20 In 2013, the median time to treatment initiation among new rifampicin-resistant patients with TB was 22 days, despite the introduction of Xpert MTB/RIF in November 2010, an assay that accurately detects rifampicin resistance in just 2 hours. 21 Indeed, Qin et al reported that less than 60% of individuals with presumptive TB were tested with Xpert MTB/ RIF while the remainder received less reliable smear microscopy. 22 Such deviations from diagnostic algorithms may partially account for the 13% of TB cases lost between TB testing and diagnosis in the patient cascade of care. 18 Furthermore, general management of patients presenting with classic TB symptoms appears to be weak. Kweza et al estimated that primary healthcare clinics, which are mostly run by qualified nurses, miss 62.9%-78.5% of patients with TB seeking healthcare for TB-related symptoms. 23 Similarly, Claassens et al reported that only 8% of individuals presenting for TB-related symptoms were screened for TB and only 3% of individuals presenting with TB-related symptoms but seeking healthcare for alternative reasons were screened at two primary healthcare facilities in Cape Town. 24 Chihota et al found that only 22% of individuals with TB-related symptoms were requested to provide a sputum sample for TB testing. 25 A recent simulated patient study from South African primary health clinics in two provinces showed that only 43% of interactions resulted in simulated patients receiving a TB sputum test and being offered an HIV test. TB sputum tests were conducted routinely (84%) while HIV tests were offered less frequently (47%). 26 The 11 country-patient pathways analysis shows that nearly one-third of South Africans seek initial care outside the public system. Private providers are less likely to order a sputum test and patients accessing private care experience longer diagnostic delays. 6 27-31 The findings of these studies reveal the magnitude of missed opportunities in the patient cascade of care that may be fuelling disease transmission.
Common THemeS from IndIA And SouTH AfrICA
The cascade of care analysis in both India and South Africa shows that a quarter of cases that reached government diagnostic centres were not diagnosed, or successfully diagnosed and lost to follow-up prior to TB treatment initiation. 11 18 Using a transmission model, a recent study in South Africa found that active case finding and loss to pretreatment follow-up were the two most effective interventions with the potential to effect a considerable impact on the TB burden. However, given the current structure of the healthcare system, reducing pretreatment loss to follow-up was predicted to be more easily achievable than active case finding, 32 due to funding and human resource constraints. 33 Furthermore, data from a recent study have indicated that current approaches to active case finding have yielded limited impact, failing to produce the expected results. In fact, the ZambiaSouth Africa TB and AIDS Reduction (ZAMSTAR) study conducted in Zambia and South Africa found that expanded active case finding had no impact on either population level or paediatric TB incidence. 34 The patient cascade of care however shows that a substantial percentage of cases engage with the public health sector revealing a major opportunity for health systems strengthening. The high burden of disease, increasing drug resistance, human resource constraints, ageing infrastructure, poor infection control practices, slow HIV/TB integration, inadequate training of healthcare workers, centralised services, poor management of the healthcare system at all levels, inadequate understanding of patient needs and a lack of empowerment of patients are just some of the myriad of barriers facing National Tuberculosis Programs (NTP) in addressing programmatic challenges. 18 33 Increasing case detection, by upscaling rapid molecular testing particularly in India and improving compliance to diagnostic algorithms in South Africa, accelerating the time to treatment initiation and enhancing linkage to care are however essential in retaining these patients. 11 Engaging the private sector to improve quality of TB care is vital to both countries, but particularly critical for India, where the private health sector dominates. To facilitate public-private mix interventions, a road map with clear action points has been recently published by WHO, Stop TB Partnership, and other stakeholders. 35 India has made significant strides in TB control by rapidly scaling up TB services, prohibiting the use of inaccurate serological tests and introducing mandatory notification of all TB cases. 3 The Indian government has recently published an ambitious National Strategic Plan (NSP) to end TB by 2025. 36 However, achieving the NSP goals will require strengthening both public and private healthcare sectors, bridging the gap between provider knowledge and practice and backing political commitments with tangible funding and investments. 37 Similarly, South Africa has published its NSP for TB and HIV 38 and made colossal investments, managing the largest ART and IPT programmes globally, leading the rollout of Xpert MTB/RIF, adopting novel and repurposed drugs into clinically proven treatment regimens while developing ambitious and comprehensive policy guidelines for the management of TB. In fact, South Africa is the largest user of both Xpert MTB/RIF and bedaquiline. However, new tools alone are insufficient. Health system issues such as addressing diagnostic delay, improving adherence to diagnostic algorithms and amplifying TB screening and testing will prove critical to enhancing the impact of new tools. Recognising this, the South African government recently launched a quality improvement (QI) programme to address the major gaps identified in the cascade of care analyses. 39 Early case detection and appropriate treatment is fundamental to TB control, the delay of which allows BMJ Global Health for disease progression, increases the risk of morbidity and mortality and perpetuates community-driven transmission. Importantly, in 2017, only 64% of the estimated incident cases of TB were reported, the remaining 36% of 'missing' cases were either undiagnosed, untreated or unreported. 1 The 'missing TB cases' have generated much hype for the challenges they present in achieving the End TB Strategy. But evidence from India and South Africa clearly suggests that these 'missed' patients are not really missing-most are actively engaging the health system (predominantly private health system in India, and predominantly public health system in South Africa). 40 The system, however, is failing to appropriately manage them. In short, quality of TB care is suboptimal and must urgently be addressed. 41 Merely focusing on coverage of TB services is no longer sufficient, as emphasised by the recent Lancet Global Health Commission on High Quality Health Systems. 42 Forty years after Alma-Ata, nearly half the world's population lacks access to essential health services. To address this crisis, countries must commit to universal health coverage (UHC). 43 A strong primary healthcare system is the backbone of UHC. However, as reviewed earlier, TB is often missed by primary care providers in both public and private sectors. So, a big challenge for the TB field is the need to rethink the traditional vertical TB care delivery model, and integrate TB care within UHC. While the vertical approach has been helpful in ensuring donor funding and technical expertise, the model's limitation has been exposed by the fact that nearly 40% of patients with TB are missing in the DOTS system. ConCluSIon TB control programme monitoring must go beyond the traditional measures of success such as effective treatment. NTPs need to identify gaps and weaknesses along the entire patient care cascade and using the science of QI to address barriers to appropriate diagnosis and linkages to treatment postdiagnosis. 17 Indeed, ending the TB epidemic will require rapid scientific advances: innovative diagnostic tools, new drugs and an effective TB vaccine. However, while the world awaits these revolutionary developments, programmatic data indicate that much can be done to accelerate the decline of TB by strengthening health systems and improving quality of care.
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